115 related articles for article (PubMed ID: 10853198)
1. [Study of various factors that could have an impact on the treatment with erythropoietin of hemodialysis anemia].
Fernández-Gallego J; Ramos B; Ruiz A; Contreras J; Alvarez Bustos G; López de Novales E
Nefrologia; 2000; 20(2):164-70. PubMed ID: 10853198
[TBL] [Abstract][Full Text] [Related]
2. Erythropoietin requirements: a comparative multicenter study between peritoneal dialysis and hemodialysis.
Coronel F; Herrero JA; Montenegro J; Fernandez C; Gandara A; Conesa J; Rivera MT; Torrente J; Portolés J; Gomez-Martino JR
J Nephrol; 2003; 16(5):697-702. PubMed ID: 14733416
[TBL] [Abstract][Full Text] [Related]
3. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
Attallah N; Osman-Malik Y; Frinak S; Besarab A
Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
[TBL] [Abstract][Full Text] [Related]
4. Factor deficiency in the anemia of renal transplant patients with grade III-IV chronic kidney disease: baseline results of the ARES Study.
Gentil MA; Pérez-Valdivia MA; López-Mendoza M; Ortega F; Arias M; Gómez-Alamillo C; Campistol JM;
Transplant Proc; 2008 Nov; 40(9):2922-4. PubMed ID: 19010148
[TBL] [Abstract][Full Text] [Related]
5. [Iron supplementation during erythropoietin therapy in patients on hemodialysis].
Svára F; Sulková S; Kvasnićka J; Polakovic V
Vnitr Lek; 1996 Dec; 42(12):849-52. PubMed ID: 9072885
[TBL] [Abstract][Full Text] [Related]
6. [Can anemia be corrected in hemodialysis patients with thalassaemia minor? ].
Di Iorio B; Guastaferro P; Gironda A; Marano V; Morrongiello L; Cillo N; Zito B; Nigro F; Frieri A; Rubino R; Bellizzi V
G Ital Nefrol; 2002; 19(5):552-9. PubMed ID: 12439845
[TBL] [Abstract][Full Text] [Related]
7. Comparison of parenteral iron sucrose and ferric chloride during erythropoietin therapy of haemodialysis patients.
Wu CJ; Lin HC; Lee KF; Chuang CK; Chen YC; Chen HH
Nephrology (Carlton); 2010 Feb; 15(1):42-7. PubMed ID: 20377770
[TBL] [Abstract][Full Text] [Related]
8. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
Li H; Wang SX
Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
[TBL] [Abstract][Full Text] [Related]
9. ACE inhibitors or angiotensin II receptor blockers in dialysed patients and erythropoietin resistance.
Saudan P; Halabi G; Perneger T; Wasserfallen JB; Wauters JP; Martin PY;
J Nephrol; 2006; 19(1):91-6. PubMed ID: 16523432
[TBL] [Abstract][Full Text] [Related]
10. The effect of high dose losartan on erythropoietin resistance in patients undergoing haemodialysis.
Odabas AR; Cetinkaya R; Selcuk Y; Keles S; Bilen H
Panminerva Med; 2003 Mar; 45(1):59-62. PubMed ID: 12682621
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
[TBL] [Abstract][Full Text] [Related]
12. The evaluation of postdialysis L-carnitine administration and its effect on weekly requiring doses of rHuEPO in hemodialysis patients.
Kadiroglu AK; Yilmaz ME; Sit D; Kara IH; Isikoglu B
Ren Fail; 2005; 27(4):367-72. PubMed ID: 16060121
[TBL] [Abstract][Full Text] [Related]
13. Role of C-reactive protein, reticulocyte haemoglobin content and inflammatory markers in iron and erythropoietin administration in dialysis patients.
El-Khatib M; Duncan HJ; Kant KS
Nephrology (Carlton); 2006 Oct; 11(5):400-4. PubMed ID: 17014552
[TBL] [Abstract][Full Text] [Related]
14. [Clinical and economic significance of iron replacement in anemia treated with recombinant human erythropoietin in patients on hemodialysis].
Vanková S; Safárová R; Horácková M; Herink J; Rychlík I; Bahbouh R; Půtová I
Cas Lek Cesk; 2001 Apr; 140(7):209-13. PubMed ID: 11374225
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin converting enzyme inhibitors impair recombinant human erythropoietin induced erythropoiesis in patients with chronic renal failure.
Qureshi IZ; Abid K; Ambreen F; Qureshi AL
Saudi Med J; 2007 Feb; 28(2):193-6. PubMed ID: 17268695
[TBL] [Abstract][Full Text] [Related]
16. Efficacy prospective study of different frequencies of Epo administration by i.v. and s.c. routes in renal replacement therapy patients.
Messa P; Nicolini MA; Cesana B; Brezzi B; Zattera T; Magnasco A; Moroni G; Campise M
Nephrol Dial Transplant; 2006 Feb; 21(2):431-6. PubMed ID: 16249199
[TBL] [Abstract][Full Text] [Related]
17. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
Nakamoto H; Mimura T; Honda N
Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
[TBL] [Abstract][Full Text] [Related]
18. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
Pizzarelli F; David S; Sala P; Icardi A; Casani A
Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298
[TBL] [Abstract][Full Text] [Related]
19. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
Silverberg DS; Blum M; Agbaria Z; Deutsch V; Irony M; Schwartz D; Baruch R; Yachnin T; Steinbruch S; Iaina A
Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241
[TBL] [Abstract][Full Text] [Related]
20. Effects of angiotensin-converting enzyme inhibitors on anemia and erythropoietin requirements in peritoneal dialysis patients.
Navarro JF; Macía ML; Mora-Fernández C; Gallego E; Chahin J; Méndez ML; del Castillo N; Rivero A; García J
Adv Perit Dial; 1997; 13():257-9. PubMed ID: 9360694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
